Vanda Pharmaceuticals Inc. VNDA

$5.00 -2.25% at last close
Market Cap$302.31 million
P/E Ratio
Div Yield
Volume1.31M
52-Week Range $4.14$9.94

Key Stats

Today's Range
$4.97 $5.17
50-Day Range
$4.45 $6.72
52-Week Range
$4.14 $9.94
Volume
1.31 million shs
Average Volume
934K shs
Market Cap
$302.31 million
P/E Ratio
Dividend Yield

Valuation

P/E Ratio
Price / Book
1.37
Price / Sales
1.40

Short Interest

Short Interest
2.58%
Days to Cover
3.94

Financials (TTM)

Revenue
$215.72 million
Net Income
$-274,853,000
Net Margin
-127.41%
Return on Equity
-124.83%
Debt-to-Equity

About Vanda Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Sector
PHARMACEUTICAL PREPARATIONS
Employees
533
Exchange
XNAS
Listed
2006-04-12

Related Stocks

Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.